CClinicalTrials.gg
CompletedNCT05742789Updated Jun 5, 2023

Effect of Anesthetics on Troponin I and С-reactive Protein

A Phase 1 interventional study of Propofol and Isoflurane in Mitral Valve Insufficiency, Aortic Valve Insufficiency and Cardiac Disease, sponsored by Astana Medical University. Completed at 1 site in Kazakhstan. Open to participants aged 50 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-06-05.

Sponsored by Astana Medical University · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Nov 2021, registered Feb 2023).
Phase
Phase 1
Study type
Interventional
Enrollment
255
Allocation
Randomized
Ages
50 Years to 65 Years
Sex
All
01

Study summary

Abstract Troponin is one of the cardiac biomarkers and its high level correlates to high risk of cardiac myocytes damage. C-reactive protein (CRP) in cardiosurgery participates in the Systemic Inflammation Response Syndrome, and heart-lung apparatus is a powerful stimulator of the systemic inflammatory reaction.

Objective: To assess effect of anesthetics on troponin I and СRP in mitral, tricuspid and aortic valve replacement/plastic in adult.

Methods. Single-center prospective randomized controlled clinical study. A total of 95 patients were assigned randomly into three groups according to the type of anesthesia: the first group of 32 patients with propofol, the second group with sevoflurane - 32 patients, and the last - 31 patients were with isoflurane.

Levels of the cardiac troponin I were calculated in ng/ml с using a portable fluorometric analyzer I-CHROMAII, manufacture of BoditechMedInc (South Korea). Normal range: \<0.04 ng/ml. CRP concentration in plasma has been determined using a biochemical analyzer Biosystems BA-200 (Spanish company, Barcelona) according to the manufacturer's instructions. The normal level of CRP is less than 5 mg/l.

Read the detailed description

The examination and treatment data of 95 patients operated in the departments of cardiovascular surgery of the City multidisciplinary hospital No. 2 were included in the study. All patients underwent mitral, aortic, tricuspid valve replacement/plasty under cardiopulmonary bypass (CPB) conditions. This research work was conducted between 2021 and 2023. To calculate the sample size, we used the formula n=t2*D*N/confidence interval*N+t2*α, which will allow to identify the static significance of the study.

Inclusion criteria: insufficiency of mitral, tricuspid and aortic valves of 3-4th degree; only planned surgeries; age range 40-60 years old; patients corresponding to II-III grade according to the scale of the American Society of Anaesthesiologists.

Exclusion criteria: pregnancy; acute coronary syndrome; hemodynamic instability.

All patients were assigned randomly into three groups according to the type of anesthesia: the first group of 32 patients with propofol, the second group with sevoflurane - 32 patients, and the last - 31 patients were with isoflurane.

The level of cardiac troponin I were calculated in ng/ml using a portable fluorometric analyzer i-CHROMAII, production of BoditechMedInc (South Korea). The normal range: \<0.04 ng/ml. The analyzer Triage® Meter Pro of Alere San Diego Inc. production (USA).

Three blood samples were taken in the patients before the anaesthesia, in 12 hours post-surgery and in 48 hours post-surgery. Blood samples were taken in the sterile test-tubes, containing no EDTA and heparin, centrifugated and stored at temperature -20 °С to avoid the erroneously low results.

CRP concentrations in plasma were determined using the biochemical analyzer Biosystems BA-200 (Spanish company, Barcelona) according to the manufacturer's instructions. The normal level of CRP is less than 5 mg/l. Blood samples were taken in the patients before the anaesthesia, 1st day post-surgery, 3rd and 5th days post-surgery.

02

Conditions studied

  • Mitral Valve Insufficiency
  • Aortic Valve Insufficiency
  • Cardiac Disease

Keywords

  • Mitral Valve Insufficiency
  • Aortic Valve Insufficiency
  • Troponin I
  • propofol
  • isoflurane
  • sevoflurane
03

In context

Heart Diseases

3,639 studies on the registry are indexed under Heart Diseases; 461 are open to participants now.

This study's enrollment of 255 is above the median of 100 across 1,778 interventional studies indexed under Heart Diseases.

Browse Heart Diseases studies →

Lead sponsor

Astana Medical University is the lead sponsor of 15 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • The age is between 50-65 years old;
  • Mitral and aortic valve insufficiency grade 3-4;
  • Participants of both sexes will be included in the study;
  • Planned surgical interventions;
  • Signed informed consent.

Exclusion criteria

Exclusion Criteria:

  • pregnancy (risk to the baby and mother)
  • hypertensive disease
  • coronary artery disease;
  • current unstable angina pectoris;
  • preoperative hemodynamic instability, defined as the use of vasopressors;
05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
255 participants (actual)

Study arms

  • Other
    Propofol

    Anesthesia

    Drug: Propofol

  • Other
    Isofluran

    Anesthesia

    Drug: Isoflurane

  • Other
    Sevofluran

    Anesthesia

    Drug: Sevoflurane

Interventions

  • DrugPropofol

    To maintain anaesthesia in Group 1 P, propofol was used as an anaesthetic in a dose of 4-6 mg/kg/h intravenously on a perfusor

    Also known as: Propofol;

  • DrugIsoflurane

    В качестве анестетика использовали изофлуран - 1,1-1,2 MAC.

  • DrugSevoflurane

    в качестве анестетика использовали севофлуран в дозе - 1,7-1,9 ПДК.

06

What researchers measure

Primary outcomes

  1. Troponin I

    Cardiac troponin I levels were calculated in ng/mL using the i-CHROMAII portable fluorescent analyzer manufactured by BoditechMedInc. (South Korea). Normal range: \<0.4 ng/mL.

    Time frame: 2 year

  2. С-reactive protein

    С-reactive protein concentrations in plasma were determined using the biochemical analyzer Biosystems BA-200 (Spanish company, Barcelona) according to the manufacturer's instructions.

    Time frame: 2 year

07

Study locations

1 site
  • Bekzat
    Astana, 0.00001, Kazakhstan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05742789
Lead sponsor
Astana Medical University
Responsible party
Bekzat Baiterek (Clinical Professor, Astana Medical University) — Principal investigator
First posted
Feb 24, 2023
Start date
Nov 30, 2021
Primary completion
Jan 4, 2023
Completion
Jan 9, 2023
Last update
Jun 5, 2023

Study contacts

Alibek Kh Mustafin, Professor
study director · Astana Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion